Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 71

Results For "board"

801 News Found

Laurus Labs acquires stake in IIT Bombay incubated ImmunoACT
News | November 20, 2021

Laurus Labs acquires stake in IIT Bombay incubated ImmunoACT

ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.


NAL drone delivers Covid-19 vaccine at a remote location
Public Health | November 15, 2021

NAL drone delivers Covid-19 vaccine at a remote location

The octocopter has successfully delivered 50 vials of Covid-19 vaccines along with syringes in a special container from Chandapura PHC to Haragadde PHC


Covaxin well tolerated with no safety concerns: Lancet
News | November 12, 2021

Covaxin well tolerated with no safety concerns: Lancet

Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%


Alembic Pharma PAT at Rs 169.29 cr. in Q2FY22
News | November 11, 2021

Alembic Pharma PAT at Rs 169.29 cr. in Q2FY22

The Board of Directors of Alembic Pharmaceuticals have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021.


AstraZeneca Pharma India PAT at Rs 11.94 cr. in Q2FY22
News | November 10, 2021

AstraZeneca Pharma India PAT at Rs 11.94 cr. in Q2FY22

The Board of Directors of AstraZeneca Pharma India have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021


Wockhardt PAT at Rs 33.53 cr. in Q2FY22
News | November 09, 2021

Wockhardt PAT at Rs 33.53 cr. in Q2FY22

The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.


Sanofi to invest up to US $ 60 million in Gyroscope
Startup | November 09, 2021

Sanofi to invest up to US $ 60 million in Gyroscope

A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).


Aurobindo Pharma PAT drops to Rs 696.99 cr in Q2FY22
News | November 09, 2021

Aurobindo Pharma PAT drops to Rs 696.99 cr in Q2FY22

The Board of Directors of Aurobindo Pharma have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021


Caplin Point Labs posts  Q2FY22 PAT at Rs 74.98 Cr
News | November 02, 2021

Caplin Point Labs posts Q2FY22 PAT at Rs 74.98 Cr

The Board of Directors of Caplin Point Laboratories at its meeting have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021


Lyka Labs  Q2FY22 consolidated PAT at Rs. 28.43Cr
News | November 01, 2021

Lyka Labs Q2FY22 consolidated PAT at Rs. 28.43Cr

Lyka Labs has reported consolidated financial results for the period ended September 30, 2021